India, Aug. 29 -- iBio Inc. (IBIO), a clinical-stage biotechnology company, released on Friday financial results for the fiscal year ending June 30, 2026, noting a wider net loss as expenses related to clinical research increased.
The company specializes in developing long-acting antibody therapeutics for obesity, cardiometabolic or cardiopulmonary diseases.
Financial Results:
For the fiscal year of 2026, iBio recorded a net loss of $33.04 million, while the same in 2025 was $18.38 million.
Revenues decreased to $0.10 million, compared to $0.40 million a year ago.
Research and Development (R&D) expenses for the year came to $19.64 million, more than double the $8.31 million reported in the previous fiscal year. The increase in expendit...